US/UK/Canada

Share

Links

Quotes

In the past, resistance mechanisms were usually thought of as static. Our study demonstrates, conversely, that a binary designation of resistance may oversimplify cancer’s true biology. These genetic mutations can fluctuate over time, and some patients can harbor more than one mutation.
Zofia Piotrowska, MD, lead author of the study
In an era where cancer treatment is increasingly personalized to the biology of each individual patient, our findings highlight the importance of molecular testing and the need for improved, noninvasive methods for serial testing.
Zofia Piotrowska, MD
In the past year, the Vice President’s moonshot initiative has brought critical attention to the need for greater collaboration and innovation in cancer research, and we are invigorated at the prospect of radiation oncology being an instrumental component of future progress. Moving forward, we must maintain the focus on advancing both the science and practice of cancer care while aligning our efforts to move Congress to authorize the $700 million requested by the President for cancer research initiatives. Substantial, predictable financial support is essential to sustain the fight to eradicate cancer.
Bruce G. Haffty, MD, FASTRO, past Chair of ASTRO’s Board of Directors
The goal of ASTRO’s 2016 Annual Meeting is to highlight the latest scientific and technological advances while emphasizing the importance of radiation oncology in providing value to cancer patients through cure and palliation.
ASTRO President David C. Beyer, MD, FASTRO
Pick a time period -
Tags ( Active)

ASTRO applauds Medicare’s final decision to cover annual, low-dose CT screening for high-risk lung cancer patients ages 55 to 77

The American Society for Radiation Oncology (ASTRO) commends the February 5, 2015, decision by the Centers for Medicare and Medicaid Services (CMS) to provide coverage for annual lung cancer screening via low-dose CT screening for those at highest-risk for lung cancer. The final Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N)  details that there is sufficient evidence to warrant annual lung cancer screening for patients most at-risk for developing lung

ASTRO commends Medicare’s decision to cover annual, low-dose CT screening for high-risk lung cancer patients ages 55 to 74

Fairfax, Va., November 14, 2014 – The American Society for Radiation Oncology (ASTRO) praises the November 11, 2014, decision by the Centers for Medicare and Medicaid Services (CMS) to provide coverage for annual lung cancer screening via low-dose CT screening for those at highest-risk for lung cancer. The Proposed Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N) confirms that there is sufficient evidence to warrant annual lung cancer screening for patients most at-risk for developing lung cancer. The Memo details the patient criteria for

ASTRO praises Medicare and Congress for protecting patient access to radiation oncology care

Medicare changes course on proposed payment cuts to radiation therapy in 2015 Medicare Physician Fee ScheduleFairfax, Va., November 3, 2014—The American Society for Radiation Oncology (ASTRO) today applauds the Centers for Medicare and Medicaid Services (CMS) for not implementing proposed payment cuts for radiation therapy starting January 1, 2015, as detailed in the final 2015 Medicare Physician Fee Schedule (MPFS), issued on Friday, October 31, 2014. ASTRO also thanks radiation oncology’s congressional champions for working with CMS to protect cancer patients’ access to radiation therapy

ASTRO applauds new CBO estimate demonstrating that ending self-referral abuse would save Medicare more than $3 billion

Fairfax, Va. April 17, 2014 — The Congressional Budget Office (CBO) today released a new assessment of the significant costs associated with physician self-referral abuse, estimating that closing the self-referral law’s loophole would save Medicare approximately $3.4 billion over a 10-year budget window. CBO’s new savings estimate—nearly double its previous estimate—adds additional weight to the existing mountain of evidence that the in-office ancillary services (IOAS) loophole results in potentially inappropriate patient care and substantial costs to the Medicare program. CBO’s savings

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media